Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com
Nevenibart Reduces Hereditary Angioedema Burden in Small Study’s Interim Analysis
At 6 months, baseline monthly rates of 0.45 for mild, 1.54 for moderate, and 0.14 for severe attacks were reduced to 0.10, 0.08, and 0.00, respectively.
Read More
Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD
Bernstein discussed recent and upcoming research and management of angioedema in patients with urticaria.
Solar Urticaria More Prevalent in Women, UV and Visible Light Both Common Triggers
Around half of participants had insufficient vitamin D levels.
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Furie discussed his experiences in evaluating therapies such as rituximab and now obinutuzumab for lupus nephritis.
Contact Dermatitis to Common Wound Care Products Exacerbates Chronic Ulcers
Fifteen of 16 patients with chronic ulcers in a small study had positive patch test to common wound care products.
Rosnilimab Demonstrates Historic Responses for Rheumatoid Arthritis
The Phase 2b RENOIR trial met its primary endpoint and key secondary endpoints in patients with RA in new 12-week data.
Barzolvolimab Improves Urticaria Control and Quality of Life
These findings were from a 52-week analysis of a Phase-2 trial in participants with chronic spontaneous urticaria.
Avapritinib Improves Outcomes in Indolent Systemic Mastocytosis in Real-World Data
Avapritinib 25mg daily significantly improved quality of life (QoL), disease control, and basal serum tryptase (BST) levels.
Machine Learning Model May Help to Diagnose Gout
Investigators hope that the model may serve as a foundation for future applications in gout diagnosis.
Copper and Iron Associated With Fibromyalgia Risk
Copper had a positive association with FM risk and iron had a negative association.
Nerandomilast Meets Primary Endpoint in Improving FVC in Progressive Pulmonary Fibrosis
Boehringer plans to soon submit a new drug application for nerandomilast for treating PPF to the FDA.
DECT Scans Unable to Detect Gout Nephropathy
Dual-energy computed tomography is able to characterize MSU in joints as well as chronic asymptomatic urolithiasis in kidneys.
FDA Approves Emblaveo Combination Antibiotic Therapy for Complicated Intra-Abdominal Infections
Emblaveo combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.
Dupilumab Reduced COPD Exacerbations Compared to Placebo
Approved under the name Dupixent in September 2024, the biologic is the first of its kind approved for COPD.
Digital Cognitive Behavioral Therapy for Fibromyalgia to be Covered by Highmark Health
Stanza previously demonstrated efficacy in helping to manage fibromyalgia in adult patients when compared with digital symptom tracking in phase 3 data.
Brensocatib, Potential First Treatment for Non-CF Bronchiectasis, Gets Priority Review
Brensocatib, also a potential first-in-class DPP1 inhibitor, has a PDUFA date of August 12, 2025.
Inhaled Triple Therapy Needs Better Integration into Asthma Care
Despite being aware of its value in treating asthma, specialists were uncertain about integrating ITT into patient care.
FDA Accepts BLA for Golimumab Biosimilar for Inflammatory Conditions
Golimumab, marketed under the names Simponi and Simponi Aria, is approved for RA, PsA, AS, and UC.
Research Identifies Non-Allergy Driven Rhinoconjunctivitis Phenotypes in Children With Asthma
Perceived Stressed Associated With Symptom Burden in People With Fibromyalgia
Endocrinological stress indicators were not associated with perceived stress, which was related to symptom severity.
Pulmonology Month in Review | January 2025
This pulmonology month in review highlights recent research on diagnosing asthma and new pivotal trial data.
Tocilizumab Biosimilar Approved for Rheumatological Diseases, COVID-19
Tocilizumab-anoh will be available in both intravenous and subcutaneous formulations.
Rheumatology Month in Review: January 2025
The rheumatology month in review emphasizes new research in gout, fibromyalgia, and psoriatic arthritis.
FDA Clears IND for Frevecitinib Asthma Inhaler
Frevecitinib is a novel inhaled dry powder therapeutic in development for asthma that remains inadequately controlled by SOC inhaled maintenance therapies.
NLR and MLR May Predict Gout Flare and CVD Mortality Risk
Levels of the neutrophil activation marker calprotectin correlated with NLR and MLR correlated with total number of gout attacks.
Nasal Epithelial Gene Expression May Allow Nasal Swab Diagnosis of Asthma Subtypes
The study also revealed a predominant T2-low asthma endotype in majority Puerto Rican and Black or African American youth populations.
Better Management Needed for Childhood Wheeze
Among multiple issues were confusing and conflicting misdiagnoses of asthma.
Fibromyalgia Common in People With IBD
People with inflammatory bowel disease and FM tended to have a higher disease duration and reported higher rates of fatigue and lower QoL.
Clinicians Challenge USPSTF Iron Deficiency Screening Recommendations in Pregnancy
Peter Kranke, MD, MBA, MME, and colleagues call for clarifications to the August 2024 recommendations with more real-world considerations.
Pegloticase + MTX for Gout Not Effective After Pegloticase Monotherapy
New research highlights the importance of immunomodulation before pegloticase exposure.